February 17, 2026

VA DOD Updates Asthma Framework

The 2025 US Department of Veterans Affairs and US Department of Defense asthma guideline introduces 21 evidence-based recommendations for primary care, redefining stepwise treatment, comorbidity management, and reliever strategy.

Conexiant

January 28, 2026

AJCC Guideline Reassessment Aims to Improve HPV-Positive Throat Cancer Staging

“The new staging will better inform clinicians and patients about a patient’s prognosis and will minimize inconsistencies in the treatments patients are offered.”

The ASCO Post

January 27, 2026

Oropharyngeal Cancer in the United States: Recent Estimates and Future Trends

A cross-sectional epidemiologic analysis found that the incidence of oropharyngeal cancer has increased among older individuals, and those with localized disease appeared to be undertreated.

The ASCO Post

November 04, 2025

New Poll: Only 1 in 3 Link Alcohol to Cancer

“Individuals who drink alcohol were more likely to believe that alcohol consumption has no effect on cancer risk, which is alarming, given the growing burden of alcohol-related cancers in the United States."

Conexiant

October 09, 2025

Pituitary Apoplexy: Lessons from Two Complex Cases

Pituitary apoplexy can represent a challenging diagnostic and management dilemma. Yet its serious nature demands immediate recognition, careful assessment and treatment by a multidisciplinary team. 

Baptist Health South Florida

June 13, 2025

FDA Approves Immune Checkpoint Inhibitor Drug for Patients With Resectable Locally Advanced Head and Neck Cancer

Pembrolizumab, an immune checkpoint inhibitor, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with resectable locally advanced head and neck squamous cell carcinoma whose tumors express PD-L1 [Combined Positive Score (CPS) ?1] as determined by an FDA-approved test.

Dana-Farber

April 27, 2025

Immunotherapy Before and After Surgery Improves Outcomes in Head and Neck Cancer

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival without the cancer coming back and higher rates of substantial tumor shrinkage prior to surgery, according to the first interim analysis of a randomized, open-label phase 3 clinical trial led by investigators from Dana-Farber Brigham Cancer Center and Washington University School of Medicine in St. Louis.

Dana-Farber

December 11, 2024

Hypoglossal Nerve Stimulation: A Novel Tool for Treating Obstructive Sleep Apnea in Children

Hypoglossal nerve stimulation is an advanced and emerging therapeutic approach designed to manage obstructive sleep apnea (OSA).

Phoenix Children's Medical Connection

July 02, 2024

Join Mount Sinai for the Eighth Annual Endoscopic Middle Ear Surgery Dissection CME Course

Friday, September 13, 7:30am- Saturday, September 14, 2:00pm

Mount Sinai New York